Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Pharmacological treatment of presbyopia by novel eye drops binocularly-instilled: pilot study

Poster Details

First Author: A. Renna SPAIN

Co Author(s):    L. Vejarano   J. Alio                 

Abstract Details


The purpose of this study was to analyse corneal multifocality generated by Presbylasik central surgery and assess post-operative results stability for a period up to of three years.


University of Alicante, Alicante; Vissum Alicante, Spain


This study included 24 eyes of 12 patients divided into two groups; 12 presbyopic myopic and 12 presbyopic hyperopic. All patients were surgically treated with central Presbylasik. Topographic measurements were conducted before the surgery and three-month, one-year and three-years after surgery. Patients’ mean age at the time of surgery was 50. Mean postoperative spherical equivalent refraction was (-0,31 ± 0,74 dioptres D) in the hyperopic group and (-0,50 ± 0,40 D) in the myopic group. With the purpose of objective analysis of corneal multifocality, a computer tool was used based on Fresnel wavefront propagation algorithm calculated from the corneal transmittance


In the hyperopic group, postoperative corneal depth of focus (DoF) was 1,55±0,45 D. At 3 year postoperatively, corneal DOF variation was 0,08±0,38 D. In the myopic group, , postoperative corneal depth of focus (DoF) was 1,93±0,25 D. At 3 year postoperatively, corneal DOF variation was 0,36±0,22 D.


Through the purely objective analysis of the cornea’s surface, it was established that the Presbylasik central technique generates an increase in corneal multifocality in the myopic group, and to a lesser extent, in the hyperopic group. Great stability of corneal DoF is observed in both groups, slightly lower in the myopic group.

Financial Disclosure:

One or more of the authors gains financially from product or procedure presented

Back to Poster listing